Results 241 to 250 of about 4,553,133 (313)
Objective The aim of this study was to evaluate the sensitivity of the 2023 American College of Rheumatology (ACR)/EULAR classification criteria for antiphospholipid syndrome (APS) in a real‐world cohort of women diagnosed with primary obstetric APS (oAPS) and to assess their ability to identify patients at risk of future pregnancy complications ...
Francesca Ruffilli +10 more
wiley +1 more source
Main Recommendations for Developing Education and Awareness Strategies for Rare Diseases: Scoping Review. [PDF]
Yamada DB +9 more
europepmc +1 more source
People with systemic autoimmune and rheumatic diseases (SARDs) are at higher risk than the general population of experiencing adverse pregnancy and perinatal outcomes such as preeclampsia, intrauterine growth restriction, and maternal and/or fetal death.
Mehret Birru Talabi, Sonya Borrero
wiley +1 more source
Aging and rare diseases: from epidemiology to a call to action. [PDF]
Mazzucato M +11 more
europepmc +1 more source
Objective This research article aims to describe the prevalence, associations, and health‐related quality of life (HRQoL) impact of mucocutaneous features of systemic lupus erythematosus (SLE). Methods Data from the Asia‐Pacific Lupus Collaboration cohort were analyzed (2013–2021).
Amanda M. Saracino +42 more
wiley +1 more source
Scoping review protocol of interventions for widening access to healthcare services in people living with rare diseases in Africa. [PDF]
Seheri M +5 more
europepmc +1 more source
Objective Cam morphology, which is a significant risk factor for hip osteoarthritis, is commonly quantified by the alpha angle (AA). This study aims to explore the potential of the triangular index ratio (TIR) to quantify cam morphology on anteroposterior radiographs by assessing the association between TIR‐defined cam morphology and the development of
Jinchi Tang +7 more
wiley +1 more source
Medicine Development and Access for Rare Diseases: Can We Do Better? [PDF]
Hollak CEM +14 more
europepmc +1 more source
Objective Hydroxychloroquine (HCQ) is a cornerstone therapy in systemic lupus erythematosus (SLE), but the weight‐based dosing does not account for clinical factors that can introduce individual variability in drug metabolism and clearance. We leveraged longitudinal data from a prospective SLE cohort to identify clinical factors that predict ...
Jay J. Patel +6 more
wiley +1 more source

